TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

PURPOSE: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, Rachel A., Gelman, Rebecca S., Anders, Carey K., Melisko, Michelle E., Parsons, Heather A., Cropp, Anne M., Silvestri, Kelly, Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisin M., Moy, Beverly, Van Poznak, Catherine H., Blackwell, Kimberly L., Puhalla, Shannon L., Jankowitz, Rachel C., Smith, Karen L., Ibrahim, Nuhad, Moynihan, Timothy J., O’Sullivan, Ciara C., Nangia, Julie, Niravath, Polly, Tung, Nadine, Pohlmann, Paula R., Burns, Robyn, Rimawi, Mothaffar F., Krop, Ian E., Wolff, Antonio C., Winer, Eric P., Lin, Nancy U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494354/
https://www.ncbi.nlm.nih.gov/pubmed/30860945
http://dx.doi.org/10.1200/JCO.18.01511

Ejemplares similares

Ejemplares similares